ARTICLE | Company News

Clovis, BMS to combine Opdivo and Rubraca in multiple cancer trials

August 4, 2017 4:46 PM UTC

Clovis Oncology Inc. (NASDAQ:CLVS) and Bristol-Myers Squibb Co. (NYSE:BMY) partnered to run multiple trials with PD-1 inhibitor Opdivo nivolumab and Clovis' PARP inhibitor Rubraca rucaparib. The companies will combine Opdivo and Rubraca in a pair of Phase III trials evaluating both the combo and each compound alone as first-line maintenance treatments of advanced ovarian cancer and triple-negative breast cancer (TNBC), respectively. Clovis will conduct the ovarian cancer trial, and BMS will conduct the TNBC trial...